

Jae Ung Jung, PhD



Jae Jung, PhD, is the Associate Chief of Emerging Science and Technology; Betsy DeWindt Endowed Chair; Chair of Microbial Sciences in Health; Director of Global Center for Pathogen and Human Health Research; Director of Experimental Therapeutics.

Dr. Jung's research focuses on virus-induced cancers, emerging viruses, therapeutics and vaccine development, and the regulation of inflammation and immunity, including host-pathogen interactions and programmed cell death. The overarching goal of his work is to uncover fundamental mechanisms of viral oncogenesis, emerging virus infections, and immune regulation, and to rapidly translate these discoveries into novel vaccines and therapeutics to advance global health.

His research has been continuously funded by federal agencies for more than three decades and is currently supported by multiple NIH awards and international collaborations. He has published over 330 articles and equally committed to education, he has mentored more than 100 postdoctoral fellows, with over 40 of his trainees now holding faculty positions worldwide, extending his legacy of training the next generation of scientists.

Dr. Jung has received numerous honors, including South Korea's 2012 Ho-Am Prize in Medicine. He is an elected Fellow of the American Academy of Microbiology and the American Association for the Advancement of Science, and his other accolades include the Leukemia and Lymphoma Society Scholar Award and the NCI Outstanding Investigator Award.

He has provided extensive service to the scientific community, serving as a standing member of three NIH study sections. He has also served as Senior Editor of *PLoS Pathogens*, Editor of the *Journal of Virology*, and Invited Editor of *PNAS*. In addition, he frequently reviews for *Nature*, *Science*, *Cell*, and their sister journals.

Dr. Jung began his career at Harvard Medical School, where he became the first Korean-born faculty to earn tenure and served as Chair of the Tumor Virology Division until 2007. He then joined the Keck School of Medicine of the University of Southern California (USC), where he held an endowed chair, served as Chair of Molecular Microbiology and Immunology, and directed the Institute for Emerging Pathogens and Immune Diseases until his recruitment to the Cleveland Clinic in 2020. He transformed infectious disease and immunology research at USC, increasing national department ranking from 61st to 9th.